Peter Kolchinsky
CIK 1384859 · Chief Executive Officer · last filed 2026-07-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.52B
Companies
41
Total Filings
115
Lifetime Open-Market Net
$1.72B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VOR | Director | 4,501,882 | $20.00 | $90.04M | -$140.27M | 7 | 2026-07-21 |
| ARTV | Director | 264,571 | $10.53 | $2.79M | $458.59M | 2 | 2026-07-20 |
| COAG | 10%+ Owner | 6,383,114 | $47.26 | $301.67M | $6.76M | 1 | 2026-06-17 |
| HOWL | 10%+ Owner | 5,076,685 | $0.45 | $2.28M | -$2.58M | 2 | 2026-06-11 |
| SGP | Director | — | $21.62 | — | $0 | 1 | 2026-02-09 |
| SION | Director | 6,899,079 | $46.55 | $321.15M | -$33.00M | 2 | 2025-11-19 |
| BCAX | Director | 2,652,575 | $26.88 | $71.30M | $164.97M | 2 | 2025-06-10 |
| JBIO | 10%+ Owner | 28,206 | $19.70 | $555.7K | $0 | 1 | 2025-04-30 |
| 89bio, Inc. (ETNB) Delisted | Director | 1,500,000 | $14.84 | $22.26M | $96.00M | 2 | 2025-02-05 |
| SEPN | Director | 5,523,915 | $33.97 | $187.65M | $375.30M | 1 | 2024-10-30 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | 703,080 | $221.38 | $155.65M | $0 | 2 | 2024-07-22 |
| ACRV | Director | — | $1.54 | — | $0 | 2 | 2024-06-24 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | 2,545,510 | $10.15 | $25.84M | $0 | 1 | 2024-05-14 | |
| ANTX | 10%+ Owner | 415,612 | $4.70 | $1.95M | $80.90M | 2 | 2023-08-22 |
| DICE Therapeutics, Inc. (DICE) Delisted | Director | 0 | $47.55 | $0 | $119.00M | 2 | 2023-08-09 |
| NKTX | Director | — | $2.22 | — | $0 | 2 | 2023-06-09 |
| SLDB | Director | — | $7.97 | — | $0 | 2 | 2023-06-08 |
| TYRA | Director | — | $30.88 | — | $0 | 2 | 2023-06-02 |
| FULC | 10%+ Owner | 9,686,628 | $3.72 | $36.03M | $7.59M | 2 | 2023-01-06 |
| IMRA | 10%+ Owner | 812,681 | $14.49 | $11.78M | $1.81M | 2 | 2022-12-12 |
| Forma Therapeutics Holdings, Inc. (FMTX) Delisted | Director | 2,750 | $20.01 | $55.0K | $80.00M | 4 | 2022-10-14 |
| WVE | Director | 17,202,009 | $5.89 | $101.32M | $121.29M | 9 | 2022-06-21 |
| Satsuma Pharmaceuticals, Inc. (STSA) Delisted | Director | 5,155,854 | $1.10 | $5.67M | $28.00M | 2 | 2022-06-07 |
| Climb Bio, Inc. (ELYM) Delisted | Director | 288,461 | $5.11 | $1.47M | $240.00M | 3 | 2022-06-01 |
| CTKB | Director | 11,054,426 | $4.46 | $49.30M | $66.28M | 2 | 2022-02-25 |
| Icosavax, Inc. (ICVX) Delisted | Director | 466,902 | $15.31 | $7.15M | $200.00M | 1 | 2021-08-04 |
| POINT Biopharma Global Inc. (RACA) Delisted | Chief Executive Officer | 1,098,318 | $10.27 | $11.28M | $0 | 2 | 2021-06-30 |
| PCVX | 10%+ Owner | 5,283,818 | $54.60 | $288.50M | -$44.98M | 1 | 2020-10-01 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Director | 0 | — | — | $0 | 3 | 2020-04-03 |
| PHAT | 10%+ Owner | 3,825,008 | $11.66 | $44.60M | $11.69M | 1 | 2020-04-03 |
| scPharmaceuticals Inc. (SCPH) Delisted | 10%+ Owner | 3,518,998 | $5.67 | $19.95M | $8.92M | 1 | 2020-02-21 |
| Synthorx, Inc. (THOR) Delisted | Director | 0 | — | — | $50.00M | 4 | 2020-01-24 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | Director | 137,176 | $38.22 | $5.24M | -$13.10M | 18 | 2019-12-02 |
| KALA | Director | 1,817 | $0.66 | $1.2K | $60.00M | 1 | 2018-10-05 |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | Director | 1,441,070 | $27.00 | $38.91M | $14.45M | 3 | 2017-10-16 |
| ACRS | 10%+ Owner | 2,125,769 | $5.33 | $11.33M | -$32.95M | 5 | 2016-09-19 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | 3,515,142 | $0.18 | $624.3K | -$23.42M | 1 | 2015-02-18 | |
| ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | 10%+ Owner | 13,913,709 | — | — | -$184.72M | 3 | 2014-09-12 |
| BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted | 10%+ Owner | 636,462 | — | — | -$8.36M | 6 | 2010-02-24 |
| ARADIGM CORP (ARDM) Delisted | 10%+ Owner | 27,035 | — | — | -$4.53M | 3 | 2008-10-31 |
| SEQUENOM INC (SQNM) Delisted | 10%+ Owner | 4,951,652 | — | — | $21.10M | 2 | 2008-06-13 |
Recent Filings · Page 2 of 12
115 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-10-30 | VOR | Sell (S) | −1,601,632 | -$41.48M | EDGAR |
| 2025-09-22 | VOR | Grant (A) | — | $0 | EDGAR |
| 2025-09-10 | VOR | Grant (A) | — | $0 | EDGAR |
| 2025-06-16 | SION | Grant (A) | — | $0 | EDGAR |
| 2025-06-10 | BCAX | Grant (A) | — | $0 | EDGAR |
| 2025-04-30 | JBIO | Other (J) | +4,249,304 | $0 | EDGAR |
| 2025-02-05 | 89bio, Inc. (ETNB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-10-30 | SEPN | Mixed | +34,979,290 | $375.30M | EDGAR |
| 2024-09-18 | BCAX | Mixed | +34,779,965 | $164.97M | EDGAR |
| 2024-07-22 | Cidara Therapeutics, Inc. (CDTX) Delisted | Mixed | +2,812,320 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.